Loading clinical trials...
Loading clinical trials...
Randomized 3-Arm Trial With Standard of Care Alone vs Either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Plus Standard of Care in Patients With Anthracycline-Associated Cardiomyopathy
Conditions
Interventions
Best Practice
Laboratory Biomarker Analysis
+2 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
July 18, 2020
Primary Completion Date
July 30, 2026
Completion Date
July 30, 2026
Last Updated
January 7, 2026
NCT07037459
NCT06874556
NCT04565665
NCT07113223
NCT01143454
NCT05836259
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions